Uwe Platzbecker, Chief Medical Officer (CMO) of the University Hospital in Dresden, shared a post on LinkedIn:
“New Insight on Imetelstat in Lower-Risk MDS
Great work by Rami Komrokji and colleagues on evaluating how prior therapy impacts the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed/refractory or ESA-ineligible lower-risk myelodysplastic syndromes. This study adds important context to optimizing treatment strategies for patients with limited options.
Title: Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS
Authors: Rami S Komrokji, Valeria Santini, Amer M Zeidan, Mikkael A Sekeres, Pierre Fenaux, Azra Raza, Moshe Mittelman, Sylvain Thépot, Rena Buckstein, Ulrich Germing, Yazan F Madanat, María Díez-Campelo, David Valcárcel, Anna Jonášová, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Shyamala Navada, Faye Feller, Michael R Savona, Uwe Platzbecker
Read the full paper here.
This follows the initial IMerge Phase 3 results published recently demonstrating clinically meaningful transfusion independence with imetelstat vs placebo.
Title: Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Authors: Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Mikkael A Sekeres, Michael R Savona, Yazan F Madanat, Maria Díez-Campelo, David Valcárcel, Thomas Illmer, Anna Jonášová, Petra Bělohlávková, Laurie J Sherman, Tymara Berry, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Ying Wan, Fei Huang, Annat Ikin, Shyamala Navada, Faye Feller, Rami S Komrokji, Amer M Zeidan
For context on how emerging data may inform treatment strategies, see this proposed therapeutic algorithm in lower-risk MDS.
Grateful to have been part of the development of this novel agent in MDS.”
Title: Treatment of lower-risk myelodysplastic syndromes
Authors: Almuth Maria Anni Merz, Uwe Platzbecker
More posts featuring Uwe Platzbecker on OncoDaily.